About this trial
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally.
CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet).
Design: an international, multicenter, retrospective case-control study of prospectively enrolled patients; low-risk intervention study as it will perform a fecal occult blood test Endpoint: predictive power of a semi-quantitative food frequency questionnaire (SQFFQ) developed for eoCRC.
Cases: Patients with a recent diagnosis of eoCRC (within 2 years from enrollment).
Controls: matched by age (matching range ± 5 years) and sex. Healthy volunteers will be mainly enrolled among workers within the participating hospital center. The enrolled healthy volunteers will perform a fecal occult blood test.
Variables of interest: age, sex, ethnicity, BMI at the time of eoCRC diagnosis and at 18 years old, country, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.
Cases only: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery, and date (if performed), chemotherapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).
Before the case-control study, three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the SQFFQ.
The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30-minute 24-h-recall computer-aided personal interview).
Primary Objective To measure the relative risk of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) for early-onset colorectal cancer in countries where eoCRC incidence is increasing versus stable/decreasing
Eligibility criteria
Qualifiers
All sexes eligible
(for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)
(for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.
Disqualifiers
CRC diagnosed at ≥ 50 years
Diseases that can modify the dietary regimen (celiac disease, diabetes)
Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)
Unable to give written consents and to fill in the electronic questionnaire
Trial design
Treatments tested in this trial
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Treatment groups
Sponsors and collaborators
San Raffaele University
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Collaborator
Ospedale Civile Guglielmo da Saliceto, Piacenza, Italy
Collaborator
Centro di Riferimento Oncologico - Aviano
Collaborator
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Collaborator
University Hospital Padova
Collaborator
Azienda Ospedaliero-Universitaria Careggi
Collaborator
IRCCS Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
Collaborator
Azienda Ospedaliera San Gerardo di Monza
Collaborator
Azienda ULSS5 Polesana, Rovigo, Italy
Collaborator
Istituto Tumori Regina Elena - IRCCS IFO, Roma, Italy
Collaborator
IRCCS De Bellis, Castellana Grotte, Italy
Collaborator
University Hospital HELIOS Klinikum Wuppertal, Center for Hereditary Tumors, University of Witten-Herdecke, Wuppertal, Germany
Collaborator
Ludwig-Maximilians - University of Munich
Collaborator
Hospital Clinic of Barcelona
Collaborator
Helsinki University Hospital, Helsinki, Finland
Collaborator
Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital, Oslo, Norway
Collaborator
University of Chicago
Collaborator
University of Colorado Hospital, CO, USA
Collaborator
University of Michigan Ann Arbor, Michigan, USA
Collaborator
Columbia University
Collaborator
The James Comprehensive Cancer Center, Columbus, OH, USA
Collaborator
Ohio State University
Collaborator
The Cleveland Clinic
Collaborator
Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
Collaborator